Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | PER2 | O15055 | 2/20 | 0.35 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | AOC2 | O75106 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24880100 | 0.81 | TSHR (0.55) | GAASMN1; SMN2POLBPRMT5WDR77 | |
| SCHEMBL4591492 | 0.79 | HSD17B10 (0.47) | GAASMN1; SMN2POLBPRMT5WDR77 | |
| SCHEMBL24879866 | 0.77 | SMN1; SMN2 (0.41) | GAASMN1; SMN2POLBALDH1A1PRMT5 | |
| SCHEMBL2825590 | 0.76 | ALDH1A1 (0.41) | GAAPOLBALDH1A1MEN1KMT2A | |
| SCHEMBL21389503 | 0.75 | SMN1; SMN2 (0.42) | GAASMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL2823420 | 0.74 | TSHR (0.65) | GAASMN1; SMN2ALDH1A1KMT2ATSHR | |
| SCHEMBL20551743 | 0.72 | PRMT5 (0.37) | GAASMN1; SMN2POLBPRMT5WDR77 | |
| SCHEMBL8741576 | 0.72 | — | — | |
| SCHEMBL12495761 | 0.72 | — | — | |
| SCHEMBL20183073 | 0.71 | TSHR (0.56) | GAASMN1; SMN2ALDH1A1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11318120-B2 | Nuclear transport modulators and uses thereof | BIOGEN MA INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210251968-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | BIOGEN MA INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-10925859-B2 | Nuclear transport modulators and uses thereof | BIOGEN MA INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10722497-B2 | Nuclear transport modulators and uses thereof | BIOGEN MA INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200230110-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | BIOGEN MA INC. (US) | 2020-07-23 | — | — | US | disclosed |
| EP-3663291-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Biogen MA Inc. (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-3404027-B1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | BIOGEN MA INC (US) | 2020-03-04 | — | — | EP | disclosed |
| US-20200038373-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT | 2020-02-06 | — | — | US | disclosed |
| US-10335393-B2 | Nuclear transport modulators and uses thereof | BIOGEN MA INC. (US) | 2019-07-02 | — | — | US | disclosed |
| EP-2858991-B1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | BIOGEN MA INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-9096543-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150111893-A1 | Nuclear Transport Modulators and Uses Thereof | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT | 2015-04-23 | — | — | US | disclosed |
| US-20150111893-A1 | Nuclear Transport Modulators and Uses Thereof | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT | 2015-04-23 | — | — | US | disclosed |
| CN-104428295-A | Nuclear transport modulators and uses thereof | KARYOPHARM THERAPEUTICS INC | 2015-03-18 | — | — | CN | disclosed |
| WO-2013170068-A2 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| EP-1937688-B1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | disclosed |
| US-7507729-B2 | for the treatment of cognitive disorders, anxiety, schizophrenia, and Alzheimer's disease; ligands; GABA A alpha 5 receptor inhibitors; 3-bromo-10-chloro-6-(2-oxo-pyrrolidin-1-ylmethyl)-9H-imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1937688-A1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007042421-A1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-19 | — | — | WO | disclosed |
| US-20070082890-A1 | Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives | BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210251968-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, XPO5, XPOT | GAA 1566/4885SMN1; SMN2 765/4885POLB 1487/4885 |
| US-20150111893-A1 | Nuclear Transport Modulators and Uses Thereof | XPO1, XPO5, XPOT | GAA 1106/4885SMN1; SMN2 489/4885POLB 1600/4885 |
| US-10925859-B2 | Nuclear transport modulators and uses thereof | XPO1, XPO5, XPOT | GAA 1557/4885SMN1; SMN2 600/4885POLB 1412/4885 |
| US-11318120-B2 | Nuclear transport modulators and uses thereof | XPO1, XPO5, XPOT | GAA 1566/4885SMN1; SMN2 765/4885POLB 1487/4885 |
| US-10335393-B2 | Nuclear transport modulators and uses thereof | XPO1, XPO5, XPOT | GAA 1102/4885SMN1; SMN2 477/4885POLB 1572/4885 |
| US-20200230110-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, XPO5, XPOT | GAA 1557/4885SMN1; SMN2 600/4885POLB 1412/4885 |
| US-20200038373-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, XPO5, XPOT | GAA 1106/4885SMN1; SMN2 489/4885POLB 1600/4885 |
| US-10722497-B2 | Nuclear transport modulators and uses thereof | XPO1, XPO5, KPNB1 | GAA 1471/4885SMN1; SMN2 892/4885POLB 1570/4885 |
| US-20070082890-A1 | Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives | GABRA5, GABRA1, GABRA4 | GAA 1252/4885SMN1; SMN2 2359/4885POLB 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.